Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-FR Version v2-FR
Language French French
Date Updated 2022-04-27 2021-12-15
Drug Identification Number 00568627 00568627
Brand name VISKAZIDE VISKAZIDE
Common or Proper name HYDROCHLOROTHIAZIDE PINDOLOL HYDROCHLOROTHIAZIDE PINDOLOL
Company Name XEDITON PHARMACEUTICALS INC XEDITON PHARMACEUTICALS INC
Ingredients HYDROCHLOROTHIAZIDE PINDOLOL HYDROCHLOROTHIAZIDE PINDOLOL
Strength(s) 25MG 10MG 25MG 10MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL ORAL ORAL
Packaging size Pack of 3 x 35 Tablets Pack of 3 x 35 Tablets
ATC code C07CA C07CA
ATC description BETA BLOCKING AGENTS AND OTHER DIURETICS BETA BLOCKING AGENTS AND OTHER DIURETICS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2021-12-20 2021-12-20
Actual start date
Estimated end date 2022-01-31 2022-01-31
Actual end date 2022-04-13
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments
Health Canada comments